

Resource Summary Report

Generated by [dkNET](#) on Sep 1, 2026

OCI-AML-5

RRID:CVCL_1620

Type: Cell Line

Proper Citation

RRID:CVCL_1620

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1620

Proper Citation: RRID:CVCL_1620

Description: Cell line OCI-AML-5 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:9096695](#), [PMID:16408098](#), [PMID:21989985](#), [PMID:22460905](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26434589](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30285677](#), [PMID:30629668](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31395879](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian., Part of: TCGA-110-CL cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: OCI-AML-5

Synonyms: OCI/AML-5, OCI-AML5, OCI/AML5, OCI AML5, OCIAML5, Ontario Cancer Institute-Acute Myeloid Leukemia-5

Cross References: BTO:BTO_0004621, CLO:CLO_0008236, EFO:EFO_0006707, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:215, BioSample:SAMN03472968, BioSample:SAMN03473389, BioSample:SAMN10988502, cancercellines:CVCL_1620, Cell_Model_Passport:SIDM00461, ChEMBL-Cells:ChEMBL4523545, ChEMBL-

Targets:CHEMBL4523576, Cosmic:787469, Cosmic:975291, Cosmic:1012111, Cosmic:1281346, Cosmic:1319548, Cosmic:2131553, Cosmic:2306234, Cosmic:2750856, Cosmic-CLP:1330983, DepMap:ACH-000065, DSMZ:ACC-247, DSMZCellDive:ACC-247, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1330983, GEO:GSM887470, GEO:GSM888550, GEO:GSM1374781, GEO:GSM1374782, GEO:GSM1446751, GEO:GSM1525023, GEO:GSM1670297, IARC_TP53:30133, LiGeA:CCLE_796, LINCS_LDP:LCL-1067, PharmacoDB:OCIAML5_1185_2019, PRIDE:PXD030304, Progenetix:CVCL_1620, PubChem_Cell_line:CVCL_1620, Wikidata:Q54931744

ID: CVCL_1620

Record Creation Time: 20220427T221355+0000

Record Last Update: 20260829T235503+0000

Ratings and Alerts

No rating or validation information has been found for OCI-AML-5.

No alerts have been found for OCI-AML-5.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lewis AC, et al. (2026) Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia. *Cell*, 189(1), 215.

Sheth AS, et al. (2025) PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway-Deficient Acute Myeloid Leukemia. *Cancer research communications*, 5(4), 648.

Decalf J, et al. (2025) Effectorless Fc-fusion improves FLT3L drug-like properties for cancer immunotherapy combinations. *EBioMedicine*, 118, 105822.

Hong J, et al. (2025) PSPC1 exerts an oncogenic role in AML by regulating a leukemic transcription program in cooperation with PU.1. *Cell stem cell*, 32(3), 463.

Guillen Magaña JN, et al. (2025) Schlafen 12 Modulation and Targeting in Acute Myeloid Leukemia. *Cancer research communications*, 5(11), 2012.

Zhang P, et al. (2025) Systematic evaluation of GAPs and GEFs identifies a targetable dependency for hematopoietic malignancies. *Cancer discovery*.

Shahzad U, et al. (2024) CASCADES, a novel SOX2 super-enhancer-associated long noncoding RNA, regulates cancer stem cell specification and differentiation in glioblastoma. *Molecular oncology*.

Mill CP, et al. (2024) Efficacy of novel agents against cellular models of familial platelet disorder with myeloid malignancy (FPD-MM). *Blood cancer journal*, 14(1), 25.

Bianchi M, et al. (2024) The CD33xCD123xCD70 Multispecific CD3-Engaging DARPin MP0533 Induces Selective T Cell-Mediated Killing of AML Leukemic Stem Cells. *Cancer immunology research*, 12(7), 921.

Park SM, et al. (2023) Dual IKZF2 and CK1 γ degrader targets acute myeloid leukemia cells. *Cancer cell*, 41(4), 726.

Mill CP, et al. (2022) Effective therapy for AML with RUNX1 mutation by cotreatment with inhibitors of protein translation and BCL2. *Blood*, 139(6), 907.

Jayavelu AK, et al. (2022) The proteogenomic subtypes of acute myeloid leukemia. *Cancer cell*, 40(3), 301.

Jin S, et al. (2020) 5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 26(13), 3371.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. *Blood cancer journal*, 9(2), 4.